Table 4 Summary of serology results by primary series and booster dose status — fall academic semester 2021, Wisconsin
Vaccine profile | Anti-S | Anti-N | Anti-S | Anti-N | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Primary series received | N | Median | 95% CI | Median | 95% CI | Vaccine platform | Median | 95% CI | Median | 95% CI | |||
Unvaccinated | 13 | -0.29 | (-0.52, 2.04) | 0.0 | (-0.77, 0.53) | n/a | -- | -- | -- | -- | |||
Fully vaccinated with primary series only | |||||||||||||
CoviShield (AstraZeneca) | 5 | 1.99 | -- | -0.63 | -- | Vector-based | 2.35 | (2.06, 2.44) | -0.32 | (-0.70, -0.07) | |||
Johnson & Johnson | 15 | 2.41 | (2.13, 2.45) | -0.29 | (-0.70, 0.09) | ||||||||
Moderna | 63 | 2.83 | (2.71, 2.90) | -0.59 | (-0.77, -0.50) | mRNA | 2.80 | (2.74, 2.86) | -0.56 | (-0.61, -0.46) | |||
Pfizer | 88 | 2.78 | (2.66, 2.87) | -0.51 | (-0.62, -0.36) | ||||||||
Covaxin | 1 | 2.01 | -- | 0.50 | -- | Inactivated whole virus | 1.87 | (1.69, 2.00) | 1.10 | (0.99, 1.30) | |||
Sinopharm | 33 | 1.66 | (1.39, 1.94) | 1.02 | (0.62, 1.25) | ||||||||
Sinovac | 45 | 1.95 | (1.82, 2.20) | 1.21 | (1.02, 1.42) | ||||||||
Primary series and mRNA booster | |||||||||||||
CoviShield (AstraZeneca) | 0 | -- | -- | -- | -- | Vector-based | 4.01 | -- | 0.29 | -- | |||
Johnson & Johnson | 5 | 4.01 | -- | -0.22 | -- | ||||||||
Moderna | 8 | 4.07 | (-0.52, 4.31) | 0.42 | (-1.30, 0.77) | mRNA | 3.82 | (3.61, 3.96) | -0.14 | (-0.70, 0.08) | |||
Pfizer | 20 | 3.69 | (3.57, 3.88) | -0.47 | (-0.98, -0.03) | ||||||||
Covaxin | 1 | 3.20 | -- | 1.22 | -- | Inactivated whole virus | 3.27 | -- | 0.29 | -- | |||
Sinopharm | 7 | 3.31 | -- | 0.07 | -- | ||||||||
Sinovac | 2 | 3.45 | -- | 0.45 | -- | ||||||||